Interstitial lung disease in polymyositis and dermatomyositis: longitudinal evaluation by pulmonary function and radiology
- PMID: 18438901
- DOI: 10.1002/art.23571
Interstitial lung disease in polymyositis and dermatomyositis: longitudinal evaluation by pulmonary function and radiology
Abstract
Objective: To estimate predictors and long-term outcome of interstitial lung disease (ILD) in patients with polymyositis (PM) and dermatomyositis (DM).
Methods: We conducted a prospective study in which newly diagnosed PM/DM patients, regardless of clinical symptoms of pulmonary disease, were investigated with repeated chest radiography, high-resolution computed tomography (HRCT) of the lungs, and pulmonary function test (PFT). Clinical, radiologic, and lung function outcome was based on the last followup results.
Results: Twenty-three patients with a mean followup period of 35 months were included. Findings on radiographic examination and/or PFT compatible with ILD were recorded in 18 patients (78%). Patients with ILD had lower lung function, higher radiologic scores, and higher creatine kinase values than those without ILD. All patients were treated with high-dose glucocorticoids and other immunosuppressive agents. Two patients died due to ILD, both with active myositis. During the followup, total lung capacity (TLC) improved in 33%, remained stable in 39%, and deteriorated in 28%. Changes in TLC correlated only partially with HRCT findings, which persisted even after normalizing for lung function.
Conclusion: ILD associated with PM/DM is in most cases mild, chronic, and has a nonprogressive course during immunosuppressive treatment. PFT can be normalized during treatment with immunosuppressive therapy, even if radiologic signs of ILD persist. The course of ILD could not be predicted on the first examination. Therefore, myositis patients with ILD need careful evaluation of clinical features as well as PFT and radiologic features during followup.
Similar articles
-
Short-term and long-term outcomes of interstitial lung disease in polymyositis and dermatomyositis: a series of 107 patients.Arthritis Rheum. 2011 Nov;63(11):3439-47. doi: 10.1002/art.30513. Arthritis Rheum. 2011. PMID: 21702020
-
Interstitial lung disease in polymyositis and dermatomyositis: clinical course and response to treatment.Semin Arthritis Rheum. 2003 Apr;32(5):273-84. doi: 10.1053/sarh.2002.50012. Semin Arthritis Rheum. 2003. PMID: 12701038
-
[Interstitial lung disease in patients with polymyositis and dermatomyositis--report of three cases].Pneumonol Alergol Pol. 2013;81(6):556-66. Pneumonol Alergol Pol. 2013. PMID: 24142786 Polish.
-
Interstitial lung disease outcomes by high-resolution computed tomography (HRCT) in Anti-Jo1 antibody-positive polymyositis patients: a single centre study and review of the literature.Autoimmun Rev. 2012 Mar;11(5):335-40. doi: 10.1016/j.autrev.2011.09.007. Epub 2011 Oct 1. Autoimmun Rev. 2012. PMID: 21985773 Review.
-
Pulmonary complications of polymyositis and dermatomyositis.Semin Respir Crit Care Med. 2007 Aug;28(4):451-8. doi: 10.1055/s-2007-985666. Semin Respir Crit Care Med. 2007. PMID: 17764062 Review.
Cited by
-
Under the dual effect of inflammation and pulmonary fibrosis, CTD-ILD patients possess a greater susceptibility to VTE.Thromb J. 2024 Apr 4;22(1):34. doi: 10.1186/s12959-024-00599-3. Thromb J. 2024. PMID: 38576023 Free PMC article. Review.
-
The molecular mechanism underlying dermatomyositis related interstitial lung disease: evidence from bioinformatic analysis and in vivo validation.Front Immunol. 2023 Oct 19;14:1288098. doi: 10.3389/fimmu.2023.1288098. eCollection 2023. Front Immunol. 2023. PMID: 37928522 Free PMC article.
-
Predictors of progression in idiopathic inflammatory myopathies with interstitial lung disease.J Transl Int Med. 2022 Nov 15;11(1):46-56. doi: 10.2478/jtim-2022-0029. eCollection 2023 Mar. J Transl Int Med. 2022. PMID: 37533847 Free PMC article.
-
The prognostic role of C-reactive protein to albumin ratio and anti-MDA5 antibody-positive in idiopathic inflammatory myopathy: a retrospective study.Sci Rep. 2023 Mar 8;13(1):3863. doi: 10.1038/s41598-023-30595-y. Sci Rep. 2023. PMID: 36890164 Free PMC article.
-
Risk factors for neuromuscular complications in lower limbs after lung transplantation.Front Neurol. 2022 Dec 6;13:1066104. doi: 10.3389/fneur.2022.1066104. eCollection 2022. Front Neurol. 2022. PMID: 36561298 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
